Difference between revisions of "Part:BBa K4586003"

Latest revision as of 17:19, 7 October 2023

ZF21.16 minCMV Promoter

Part Description

This part codes for conditional promoter its activity based on VP64 transcription factor This promoter is designed to contain multiple repeats recognized by the zinc finger protein 21.16 to direct VP64 activity toward this promoter.it has a high level of transcriptional activity, and it is demonstrated that ZF21 encourages focal adhesion turnover and ECM breakdown at the invadopodia, which suppresses tumor growth.

Usage

This conditioned promoter is implemented in our design as it has a high level of transcriptional activity and is regulated by the VP64 released from the internal domain of our syn notch receptor. The ZF21.16 promoter is used in our design to control the expression of our cargo circuit or our therapeutic agent, which contains (switch + Cas12/gBAFF-R), which has a high level of transcriptional activity and is regulated by the VP64 released from the internal domain of our syn notch receptor as shown in figure 1.

Figure 1: This figure illustrates the design of our biological circuit expressing our therapeutic agent under the control of the VP64 transcription module that regulates the activity of the ZF21.16minCMV promoter.

charactrization by mathematical modeling

We are using mathematical modeling to simulate the effect of activation on the internal domain on the level of expression of our engineered exosomes so on activation of Zinc finger proteins (ZF21.16) which represent a part of the internal domain that leads to release the transcription factor VP64 which activate (ZF21.16 minCMV) promoter to start transcription of the internal circuit that secretes the exosome's cargo then cargo loading to exosomes through loading system (CD63-L7Ae).

Figure 1: The graph shows the relation between activation of the internal domain of synthetic notch and increased level of engineered exosomes.

Sequence and Features

Assembly Compatibility:

10
COMPATIBLE WITH RFC[10]
12
COMPATIBLE WITH RFC[12]
21
COMPATIBLE WITH RFC[21]
23
COMPATIBLE WITH RFC[23]
25
COMPATIBLE WITH RFC[25]
1000
COMPATIBLE WITH RFC[1000]

@@ Line 23: / Line 23: @@
 <p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 lang=EN style='font-size:11.0pt;line-height:115%'>Figure 1: This figure illustrates the design of our biological circuit expressing our therapeutic agent under the control of the VP64 transcription module that regulates the activity of the ZF21.16minCMV promoter.   </span></p></div></html>
+<br><br>
+==charactrization by mathematical modeling==
+We are using mathematical modeling to simulate the effect of activation on the internal domain on the level of expression of our engineered exosomes so on activation of Zinc finger proteins (ZF21.16) which represent a part of the internal domain that leads to release the transcription factor VP64 which activate (ZF21.16 minCMV) promoter to start transcription of the internal circuit that secretes the exosome's cargo then cargo loading to exosomes through loading system (CD63-L7Ae).
+<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              	max-width:850px;
+							width:100%;
+							height:auto;
+								position: relative;
+							top: 50%;
+							left: 45%;
+							transform: translate( -50%);
+							padding-bottom:25px;
+							padding-top:25px;
+							"src="https://static.igem.wiki/teams/4586/wiki/modeling/0003.png">
+<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+lang=EN style='font-size:11.0pt;line-height:115%'>Figure 1: The graph shows the relation between activation of the internal domain of synthetic notch and increased level of engineered exosomes.   </span></p></div></html>
 <!-- Add more about the biology of this part here